| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JACC.2007.03.071 |
| P8608 | Fatcat ID | release_7eb2thqbxfctndnznsxakwuefe |
| P698 | PubMed publication ID | 17980248 |
| P5875 | ResearchGate publication ID | 5866879 |
| P50 | author | David P Kao | Q42874948 |
| P2093 | author name string | Michael B Fowler | |
| Ronald M Witteles | |||
| Randall H Vagelos | |||
| Donald Schreiber | |||
| Dianne Christopherson | |||
| Kelly Matsuda | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| placebo | Q269829 | ||
| acute decompensated heart failure | Q4677930 | ||
| P304 | page(s) | 1835-1840 | |
| P577 | publication date | 2007-10-23 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. | |
| P478 | volume | 50 |
| Q22306346 | 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration |
| Q51666642 | Acute Effects of Intravenous Nesiritide on Cardiac Contractility in Heart Failure |
| Q38013693 | Acute kidney injury clinical trial design: old problems, new strategies. |
| Q37078768 | Approach to hemodynamic shock and vasopressors |
| Q37768079 | CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease |
| Q36865182 | Cardiorenal Syndrome Type 1: Renal Dysfunction in Acute Decompensated Heart Failure |
| Q85199143 | Cardiorenal syndrome |
| Q34532094 | Cardiorenal syndrome type 2: from diagnosis to optimal management |
| Q38068097 | Cardiorenal syndrome: pathophysiology and potential targets for clinical management |
| Q37696360 | Cardiorenal syndrome: still not a defined entity |
| Q33571255 | Continuous administration of recombinant human B-type natriuretic peptide can improve heart and renal function in patients after cardiopulmonary bypass surgery |
| Q26822842 | Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach |
| Q48521462 | Effect of intermittent nesiritide administration on kidney function. |
| Q48692760 | Effect of nesiritide in isolated right ventricular failure secondary to pulmonary hypertension. |
| Q37688147 | Efficacy and safety of nesiritide in patients with acute decompensated heart failure. |
| Q28078389 | Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials |
| Q39258545 | Evolving treatment strategies for management of cardiorenal syndrome |
| Q37258795 | Insights into natriuretic peptides in heart failure: an update |
| Q41217019 | Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome |
| Q35132420 | Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review |
| Q43117868 | Low-dose nesiritide improves renal function in heart failure patients following acute myocardial infarction |
| Q37590471 | Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome |
| Q37329891 | Modulation of cGMP in heart failure: a new therapeutic paradigm |
| Q38509576 | Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials |
| Q34906050 | Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications |
| Q46257871 | Nesiritide improves hemodynamics in children with dilated cardiomyopathy: a pilot study |
| Q33878162 | Nesiritide in acute decompensated heart failure: current status and future perspectives |
| Q37217350 | Nesiritide: the clinical experience |
| Q37086309 | Overview of emerging pharmacologic agents for acute heart failure syndromes |
| Q37552943 | Overview of emerging pharmacotherapy in chronic heart failure |
| Q37089975 | Pharmacologic Management of the Cardio-renal Syndrome |
| Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
| Q37821626 | Pharmacotherapy for acute heart failure syndromes |
| Q34117741 | ROSE-AHF and lessons learned |
| Q37694008 | Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure |
| Q33578212 | Silent disease progression in clinically stable heart failure |
| Q47855200 | Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure |
| Q37425473 | Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial |
| Q48136990 | The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure. |
| Q35672997 | The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials |
| Q48571102 | The effect of nesiritide on renal function and other clinical parameters in patients with decompensated heart failure and preserved ejection fraction. |
| Q35574190 | The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury |
| Q43123466 | The tumultuous journey of nesiritide: past, present, and future |
Search more.